Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
KKR Genetic Disorder L.P. - 12 May 2025 SCHEDULE 13D/A Report for BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share (BBIO)
- Filing manager
- KKR Genetic Disorder L.P.
- Reporting owner
- KKR Genetic Disorder L.P.
- Beneficially owned shares
- 13,260,971 shares
- Large-stake signal
-
Ownership
7%Beneficial ownership of this reported class.
Shares
13,260,971 sharesShares beneficially owned as disclosed.
Event date
12 May 2025Date tied to the ownership event or amendment.
Accepted by SEC
14 May 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 7%
- Symbol
- BBIO
- Shares outstanding
- 189,442,443 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 14 May 2025, 17:52:58 UTC
- Event date
- 12 May 2025
- Prior SEC filing
- 07 Mar 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
KKR Genetic Disorder L.P. disclosed 7% ownership in BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share (BBIO) on 12 May 2025.
Key facts
- KKR Genetic Disorder L.P. filed SCHEDULE 13D/A for BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share (BBIO).
- Disclosed ownership: 7%.
- Date of event: 12 May 2025.
Change
- Previous schedule filing date: 07 Mar 2025.
- Current filing was accepted on 14 May 2025, 17:52.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (9)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Assistant Secretary, KKR Genetic Disorder GP LLC, its general partner | 0001780408 |
| KKR Genetic Disorder GP LLC | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Assistant Secretary | |
| KKR Group Partnership L.P. | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Secretary, KKR Group Holdings Corp., its general partner | |
| KKR Group Holdings Corp. | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Secretary | |
| KKR Group Co. Inc. | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Secretary | |
| KKR & Co. Inc. | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Secretary | |
| KKR Management LLP | 7% | 13,260,971 | 13,260,971 | 0 | /s/ Christopher Lee | Christopher Lee, Assistant Secretary | |
| Henry R. Kravis | 7% | 13,260,971 | 0 | 13,260,971 | /s/ Christopher Lee | Christopher Lee, Attorney-in-fact | |
| George R. Roberts | 7% | 13,260,971 | 0 | 13,260,971 | /s/ Christopher Lee | Christopher Lee, Attorney-in-fact |
CIK / CUSIP context first